Clinical trials: Pulmonary Hypertension (PH)
Pulmonary Arterial Hypertension (PAH)
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH).
- Trial name
- ILLUMINATE (NCT07318597)
- Testing
- REGN13335
- Where
- 33 sites in United States, Australia and 8 more
- Volunteers
- 99 people
- Sponsor
- Regeneron Pharmaceuticals
Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease
An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The purpose of this study is to provide continued access to TPIP for participants who have successfully completed the open-label extension (OLE) studies of INS1009-203 for PAH or INS1009-212 for PH-ILD.
- Trial name
- NCT06939647
- Testing
- Treprostinil Palmitil
- Sponsor
- Insmed Incorporated
Pulmonary Hypertension, Interstitial Lung Disease (ILD)
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a…
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases
- Trial name
- NCT07333183
- Testing
- inhaled mosliciguat, Dry Powder Inhaler
- Where
- 13 sites in United States
- Volunteers
- 20 people
- Sponsor
- Pulmovant, Inc.
Pulmonary Arterial Hypertension
Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients
This was a non-confirmatory, randomized, placebo controlled, subject and investigator blinded study of QCC374 in PAH subjects. The study was planned to have 2 Parts: Part 1, an initial safety cohort with a 0.03 mg bid starting…
- Trial name
- NCT02927366
- Testing
- QCC374
- Where
- 5 sites in United States, Germany and 2 more
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Hypertension
Pulmonary Hypertension Registry Switzerland
Registry Data from PH-patients in Switzerland, who have given consent to records for research purposes.
- Trial name
- NCT05610631
- Where
- Switzerland
- Volunteers
- 1,000 people
- Sponsor
- University of Zurich
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD
This is a placebo-controlled, double-blind, parallel, randomized, two-part, dose-confirming clinical study characterizing the pharmacodynamic effects of pulsed iNO using the combination product, inhaled nitric oxide/INOpulse DS-C…
- Trial name
- NCT01728220
- Testing
- Inhaled NO delivered via INOpulse DS-C Device
- Where
- 43 sites in United States
- Volunteers
- 159 people
- Sponsor
- Bellerophon Pulse Technologies
Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension
Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)
This is a phase 2, Multi-center, double-blind, randomized, placebo-controlled study to evaluate the effects of inhaled Iloprost in patients with pulmonary hypertension secondary to COPD.
- Trial name
- NCT01437878
- Testing
- Iloprost
- Where
- 11 sites in United States, France and 1 more
- Volunteers
- 2 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
PulmonAry hyperteNsion DiagnOsis: a National cohoRt reseArch
Understanding Delays in the Diagnosis of Pulmonary Arterial Hypertension and Rare Diseases in Brazil: A Multicenter Observational Study --- Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening…
- Conditions
- Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension
- Trial name
- PANDORA (NCT06998329)
- Testing
- There will be no intervention
- Where
- Brazil
- Volunteers
- 139 people
- Sponsor
- University of Sao Paulo General Hospital
Pulmonary Hypertension
Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension
Pulmonary hypertension or elevation of the pressure in the pulmonary vessels, results from various clinical conditions. It may be idiopathic (of unknown cause) or associated with numerous diseases including cardiovascular and…
- Trial name
- PB-02 (NCT02216279)
- Testing
- PulmoBind
- Where
- 3 sites in Canada
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Montreal Heart Institute
Pulmonary Arterial Hypertension
A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)
This is an exploratory Phase 2a, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of RVT-1201 in patients with…
- Trial name
- NCT03924154
- Testing
- RVT-1201
- Where
- 23 sites in United States, Canada
- Volunteers
- 3 people
- Sponsor
- Altavant Sciences GmbH
Group 3 Pulmonary Hypertension
Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD (Windward)
The goal of this clinical trial is to see if mirivadelgat will work in participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD). It will also learn about the safety of mirivadelgat.
- Trial name
- WINDWARD (NCT06475781)
- Testing
- Mirivadelgat
- Where
- 11 sites in Bosnia and Herzegovina, Taiwan
- Volunteers
- 126 people
- Sponsor
- Foresee Pharmaceuticals Co., Ltd.
Pulmonary Hypertension
Acute Effects of rhBNP in Patients With PH Associated With Acute Exacerbation of Chronic Pulmonary Disease
To evaluate the acute effect of recombinant human brain natriuretic peptide(rhBNP) on pulmonary hypertension of acute exacerbations of chronic pulmonary disease.
- Trial name
- NCT02742909
- Testing
- rhBNP
- Where
- China
- Volunteers
- 9 people
- Sponsor
- LI ZHAO
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
The Effect of Slow-Paced Breathing on Patient Outcomes in Pulmonary Arterial Hypertension
This study aims to investigate the effects of slow-paced breathing (SPB) intervention applied to patients with pulmonary arterial hypertension (PAH) in the home environment on symptom management (dyspnea, fatigue, sleep quality)…
- Trial name
- NCT07232368
- Testing
- Slow-paced breathing intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 42 people
- Sponsor
- Ege University
Pulmonary Hypertension
Effect of Endothelin-1 Receptor Blockade on Circulating Endothelial Microparticles Levels in Patients With Pulmonary Hypertension
Pulmonary hypertension is a progressive and life threatening condition. It is characterized by severe remodeling of the pulmonary vessel wall, obstructive plexiform lesions, multi-focal thrombosis, and enhanced vasoconstriction.
- Trial name
- NCT00675051
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Pulmonary Hypertension Due to Left Heart Disease, Heart Failure With Preserved Ejection Fraction
Training in HFpEF-PH
Exercise interventions alone or as a component of a comprehensive cardiac rehabilitation program for patients with heart failure (HFrEF and HFpEF) have already shown to reduce the risk of hospitalisations due to HF and improved…
- Trial name
- TRAIN HFpEF (NCT05464238)
- Testing
- Exercise rehabilitation, Standard treatment
- Where
- 2 sites in Germany, Lithuania
- Volunteers
- 90 people
- Sponsor
- Heidelberg University
Hypertension, Pulmonary
Catheter Denervation of Pulmonary Arteries in Treatment of IPAH & SPAH
The aim of research proposal is to assess and compare the safety and efficacy of radiofrequency denervation of pulmonary arteries on decrease in pulmonary vascular resistance and mean pulmonary artery pressure (MPAP) in 20…
- Trial name
- CADOPA (NCT02403908)
- Testing
- nMARQ Circular and Crescent catheters
- Where
- Croatia
- Volunteers
- 60 people
- Sponsor
- Clinical Hospital Centre Zagreb
Pulmonary Hypertension
Pulmonary Hypertension and Arrhythmia
Patients with pulmonary hypertension underwent (routine) Holter ECG and were screened for (malignant) arrhyhtmias. Results of Holter ECGs were correlated with clinicial and technical data (echocardiography and right heart…
- Trial name
- NCT05496504
- Testing
- Holter ECG
- Volunteers
- 222 people
- Sponsor
- Asklepios Neurological Clinic Bad Salzhausen
Pulmonary Hypertension, Interstitial Lung Disease
An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE
This is a multicenter, open-label trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined…
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
- Trial name
- NCT02633293
- Testing
- Inhaled Treprostinil
- Where
- 92 sites in United States, Puerto Rico
- Volunteers
- 243 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension (PH)
COMPERA / COMPERA-KIDS
In view of the manifold options for mono- and combination therapy that have now emerged for patients with pulmonary (arterial) hypertension (PH/PAH), controlled clinical trials can only provide part of the information needed for…
- Trial name
- COMPERA (NCT01347216)
- Where
- 7 sites in Belgium, Germany and 2 more
- Volunteers
- 14,000 people
- Sponsor
- Technische Universität Dresden
Obstructive Sleep Apnea, Pulmonary Hypertension
Role of Heme-oxygenase (HO) and Nitric Oxide (NO) Pathway in Patients With Obstructive Sleep Apnea (OSA) and Pulmonary Hypertension (PH)
Research design: This is a controled prospective study. Methodology: Patients with newly diagnosed and untreated OSA with total apnea-hypopnea index (AHI) >5/h, and control (AHI<5/h) will be recruited from the Long Beach VA sleep…
- Trial name
- NCT02368171
- Testing
- measure exhaled carbon monoxide and nitric oxide
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Southern California Institute for Research and Education